SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:kth-273182"
 

Sökning: onr:"swepub:oai:DiVA.org:kth-273182" > Altered levels of C...

Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers

Remnestål, Julia (författare)
KTH,Affinitets-proteomik,Science for Life Laboratory, SciLifeLab,Nilsson Lab
Öijerstedt, Linn (författare)
Karolinska Institutet
Ullgren, Abbe (författare)
Karolinska Institutet
visa fler...
Olofsson, Jennie (författare)
KTH,Science for Life Laboratory, SciLifeLab,Affinitets-proteomik,Nilsson Lab
Bergström, Sofia (författare)
KTH,Science for Life Laboratory, SciLifeLab,Affinitets-proteomik,Nilsson Lab
Kultima, Kim (författare)
Uppsala Universitet
Ingelsson, Martin (författare)
Uppsala Universitet
Kilander, Lena (författare)
Uppsala Universitet
Uhlén, Mathias (författare)
KTH,Science for Life Laboratory, SciLifeLab,Albanova VinnExcellence Center for Protein Technology, ProNova,Systembiologi
Månberg, Anna, 1985- (författare)
KTH,Science for Life Laboratory, SciLifeLab,Affinitets-proteomik,Nilsson Lab
Graff, Caroline (författare)
Karolinska Institutet
Nilsson, Peter (författare)
KTH,Science for Life Laboratory, SciLifeLab,Affinitets-proteomik,Nilsson Lab
visa färre...
 (creator_code:org_t)
Engelska.
Ingår i: Translational Neurodegeneration. - 2047-9158.
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background. The clinical presentations of frontotemporal dementia (FTD) are diverse and overlap with other neurological disorders. There are, as of today, no biomarkers in clinical practice for diagnosing the disorders. Here, we aimed to find protein markers in cerebrospinal fluid (CSF) from patients with FTD, presymptomatic mutation carriers and non-carriers.Methods. Antibody suspension bead arrays were used to analyse 328 proteins in CSF from patients with behavioural variant FTD (bvFTD, n=16) and progressive primary aphasia (PPA, n=13), as well as presymptomatic mutation carriers (PMC, n=16) and non-carriers (NC, n=8). A total of 492 antibodies were used to measure protein levels by direct labelling of the CSF samples. The findings were further examined in an independent cohort including 13 FTD patients, 79 patients with Alzheimer’s disease and 18 healthy controls.Results. We found significantly altered protein levels in CSF from FTD patients compared to unaffected individuals (PMC and NC) for 26 proteins. The analysis show patterns of separation between unaffected individuals and FTD patients, especially for those with a clinical diagnosis of bvFTD. The most statistically significant differences in protein levels were found for VGF, TN-R, NPTXR, TMEM132D, PDYN and NF-M. Patients with FTD were found to have higher levels of TN-R and NF-M, and lower levels of VGF, NPTXR, TMEM132D and PDYN, compared to unaffected individuals. The main findings were reproduced in the independent cohort.Conclusion. In this pilot study, we show a separation of FTD patients from unaffected individuals based on protein levels in CSF. Further investigation is required to explore the CSF profiles in larger cohorts, but the results presented here has the potential to enable future clinical utilization of these potential biomarkers within FTD.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Neurosciences (hsv//eng)

Nyckelord

Frontotemporal dementia
cerebrospinal fluid
biomarkers
proteomics
antibody suspension bead array
Biotechnology
Bioteknologi

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy